Surveillance of omadacycline activity tested against clinical isolates from the United States and Europe: Results from the SENTRY Antimicrobial Surveillance Programme, 2017.
Anti-Bacterial Agents
/ pharmacology
Community-Acquired Infections
/ microbiology
Drug Resistance, Multiple, Bacterial
/ drug effects
Europe
Gram-Negative Bacteria
/ drug effects
Gram-Positive Bacteria
/ drug effects
Humans
Methicillin-Resistant Staphylococcus aureus
/ drug effects
Microbial Sensitivity Tests
Streptococcus pneumoniae
/ drug effects
Tetracyclines
/ pharmacology
United States
United States Food and Drug Administration
Multidrug resistance
Omadacycline
Staphylococcus aureus
Streptococcus pneumoniae
Surveillance
Journal
Journal of global antimicrobial resistance
ISSN: 2213-7173
Titre abrégé: J Glob Antimicrob Resist
Pays: Netherlands
ID NLM: 101622459
Informations de publication
Date de publication:
12 2019
12 2019
Historique:
received:
12
11
2018
revised:
01
02
2019
accepted:
19
02
2019
pubmed:
3
3
2019
medline:
21
7
2020
entrez:
3
3
2019
Statut:
ppublish
Résumé
Omadacycline is an aminomethylcycline antibacterial (oral and intravenous once-daily formulation) that recently (October 2018) received United States Food and Drug Administration (FDA) approval for the treatment of acute bacterial skin and skin structure infections (ABSSSIs) and community-acquired bacterial pneumonia (CABP) against selected organism groups. This study tested omadacycline and comparators against 14 000 non-duplicate bacterial isolates that were prospectively collected during 2017 from medical centres in Europe (EUR; 7000 isolates) and the United States (USA; 7000 isolates). Omadacycline was tested by broth microdilution following Clinical and Laboratory Standards Institute M07-A11 (2018) methods. A total of 98.7% ofStaphylococcus aureus isolates were susceptible to omadacycline (MIC The potent activity of omadacycline against Gram-positive and Gram-negative bacteria indicates that omadacycline merits further study in serious infections in which multidrug resistance and mixed Gram-positive and Gram-negative infections may be of concern.
Identifiants
pubmed: 30825698
pii: S2213-7165(19)30057-8
doi: 10.1016/j.jgar.2019.02.017
pii:
doi:
Substances chimiques
Anti-Bacterial Agents
0
Tetracyclines
0
omadacycline
090IP5RV8F
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
56-63Informations de copyright
Copyright © 2019 International Society for Chemotherapy of Infection and Cancer. Published by Elsevier Ltd. All rights reserved.